

A. Un-Audited Financial Results(Provisional) for the Quarter ended 30th June 2012					(Rs. in Lacs)
Sr. No.	Particulars	Unaudited			Audited
		Quarter ended			Year ended
		3 months ended	Corresponding 3 months ended in the previous year	Corresponding 3 months ended	Current accounting year ended
	30.06.12	30.06.11	31.03.12	31.03.12	
1	Sales/Income from operation(Net of Excise duty)	2375.92	3450.76	4003.68	15318.19
2	Other Operating Income	49.76	2.14	54.22	60.43
3	Total Net Income from Operation	2425.68	3452.90	4057.90	15378.62
4	Expenditure				
	(a) Increase / decrease in stock in trade & work in progress	667.50	(363.16)	(1186.64)	(1576.15)
	(b) Consumption of raw materials	1360.44	2727.45	4761.49	12444.85
	(c) Employees Cost	218.31	207.24	222.15	900.97
	(d) Depreciation	93.41	81.18	98.51	373.64
	(e) Other expenditure	452.80	490.07	78.61	2140.08
	(f) Total	2792.46	3122.79	3994.12	14283.37
5	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	(366.78)	330.11	63.78	1095.25
6	Other income	0.99	0.98	28.98	34.97
7	Profit (+) / Loss (-) from ordinary activities before Finance Cost & Exceptional Items(5+6)	(365.79)	331.09	92.76	1130.22
8	Finance Cost	236.89	206.09	303.97	1016.43
9	Profit(+)/Loss(-) from ordinary activities after Finance cost & Exceptional Items(7-8)	(602.68)	125.00	(211.21)	113.79
10	Exceptional Items	0.00	0.00	0.00	0.00
11	Profit(+)/Loss(-) before Tax (9-10)	(602.68)	125.00	(211.21)	113.79
12	Tax Expenses(incl Deferred Tax)	0.00	40.00	(18.58)	50.42
13	Net Profit(+)/Loss(-) after Tax (11-12)	(602.68)	85.00	(192.63)	63.37
14	Extraordinary Items	0.00	0.00	0.00	0.00
15	Net Profit(+)/Loss(-) for the period(13-14)	(602.68)	85.00	(192.63)	63.37
16	Paid up Equity Share Capital (face value Rs. 10/-each)	1317.82	1317.82	1317.82	1317.82
12	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	0.00	0.00	2488.35	2488.35
13	Earning per share (EPS)				
	(a) Basic and diluted EPS before extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(4.57)	0.65	(1.46)	0.48
	(b) Basic and diluted EPS after extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	(4.57)	0.65	(1.46)	0.48
14	Non Promoters Shareholding				
	- Number of shares	7548453	7610239	7518093	7518093
	- Percentage of shareholding	57.28	57.75	57.05	57.05
15	Promoters and Promoter group Shareholding				
	a) Pledged/ Encumbered				
	Number of Shares	1441095	3316095	1441095	1441095
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	25.59	59.56	25.46	25.46
	Percentage of Shares (as a % of the total share capital of the company)	10.94	25.16	10.94	10.94
	b) Non-encumbered				
	Number of Shares	4188700	2251914	4219060	4219060
	Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	74.41	40.44	74.54	74.54
	Percentage of Shares (as a % of the total share capital of the company)	31.78	17.09	32.01	32.01


Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 13th August 2012.
- During the Quarter & Year ended 30th June 2012, 0 Investor complaint were received, all of which have been attended by the company. No complaints were pending at the beginning or at the end of the quarter.
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 13.08.2012

On behalf of Board of Directors
For Mangalaram Drugs & Organics Ltd.

Director
(Shri Govardhan M. Dhoot)



B. Segment Performance - Revenue and Results

Sr. No.	Particulars	Unaudited			(Rs In Lacs)
		Quarter Ended			Audited
		Current Quarter ended 30.06.12	Corresponding 3 months ended 30.06.11 in the previous year	Corresponding 3months ended 31.03.12	Year to date figures for the current year ended 31.03.12
1	Segment Revenue				
a)	Bulk Drugs	2375.92	3450.76	4003.68	15318.19
	Total Revenue	2375.92	3450.76	4003.68	15318.19
2	Segment Results				
a)	Bulk Drugs	(120.17)	533.07	380.55	2215.09
	Total Segement Results before interest and tax	(120.17)	533.07	380.55	2215.09
	Less : i) Interest**	(236.89)	(206.09)	(303.97)	(1016.43)
	(ii) Other Un-allocable Expenditure	(245.62)	(201.98)	(287.79)	(1084.87)
	Total Profit/(Loss) Before Tax	(602.68)	125.00	(211.21)	113.79

Note:

Certain assets of the company are used by different segments for different portion of the accounting period. Hence the value of the assets cannot be allocated to the segments.
Current year and Previous years figures are regrouped/rearranged wherever necessary


On behalf of Board of Directors

For Mangalam Drugs & Organics Ltd.

Director

Shri. Govardhan M.Dhoot

Place: Mumbai
Date: 13th, August 2012



CA Rakesh K. Milwani
B.Com., L.L.B., FCA.



MILWANI ASSOCIATES

CHARTERED ACCOUNTANTS

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001.

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.

LIMITED REVIEW REPORT


We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at 292, Princess Street, Second Floor, Near Flyover, Mumbai - 400 002; for the quarter ended 30th June, 2012 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai

Date : 13th August, 2012.



PROPRIETOR, MILWANI ASSOCIATES

Membership No.36099

f.k.n. 106405W